Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorPASQUALINI, Claudia
dc.contributor.authorFURTWAENGLER, Rhoikos
dc.contributor.authorTINTEREN, Harm van
dc.contributor.authorTEIXEIRA, Roberto A. P.
dc.contributor.authorACHA, Tomas
dc.contributor.authorHOWELL, Lisa
dc.contributor.authorVUJANIC, Gordan
dc.contributor.authorGODZINSKI, Jan
dc.contributor.authorMELCHIOR, Patrick
dc.contributor.authorSMETS, Anne M.
dc.contributor.authorCOULOMB-L'HERMINE, Aurore
dc.contributor.authorBRISSE, Herve
dc.contributor.authorPRITCHARD-JONES, Kathy
dc.contributor.authorBERGERON, Christophe
dc.contributor.authorCAMARGO, Beatriz de
dc.contributor.authorHEUVEL-EIBRINK, Marry M. Van den
dc.contributor.authorGRAF, Norbert
dc.contributor.authorVERSCHUUR, Arnauld C.
dc.identifier.citationEUROPEAN JOURNAL OF CANCER, v.128, p.38-46, 2020
dc.description.abstractIntroduction: High-risk (HR) metastatic (stage IV) Wilms tumours (WTs) have a particular poor outcome. Methods: Here, we report the results of HR (diffuse anaplastic [DA] or blastemal type [BT]) stage IV WT treated patients according to the HR arm in the SIOP2001 prospective study. Results: From January 2002 to August 2014, 3559 patients with WT were included in the SIOP2001 trial. Among the 525 patients (15%) with metastatic WT, 74 (14%) had stage IV HR-WT. The median age at diagnosis was 5.5 years (range: 1.4-18.3). Thirty-four patients (47%) had BT-WT and 40 (53%) had DA-WT. Five-year event-free survival rates were 44 +/- 17% and 28 +/- 15% for BT-WT and DA-WT, respectively (p = 0.09). Five-year overall survival rates were 53 +/- 17% and 29 +/- 16% for BT-WT and DA-WT, respectively (p = 0.03). Metastatic complete response after preoperative treatment was significantly associated with outcome in univariate and multivariate analyses (hazards ratio = 0.3; p = 0.01). Postoperative radiotherapy of metastatic sites might also be beneficial. Forty-three of 74 patients experienced a relapse or progression predominantly in the lungs (80%). The median time to relapse/ progression after diagnosis was 7.3 months (range: 1.6e33.3) and 4.9 months (range: 0.7 -28.4) for BT-WT and DA-WT, respectively (p Z 0.67). This is the first prospective evidence of inferior survival of stage IV BT-WT as compared with historical intermediate-risk WT. Survival of patients with stage IV DA-WT has not improved compared to the previous SIOP93-01 study. Conclusion: These results call for new treatment approaches for patients with HR stage IV WT.eng
dc.description.sponsorshipGerman CancerAid (Deutsche Krebshilfe)Deutsche Krebshilfe [50-2709-GR2]
dc.description.sponsorshipAssociation Leon Berard Enfant Cancereux
dc.description.sponsorshipEnfant et Sante(Albec)
dc.description.sponsorshipDaDa Society (Nieuwerkerk a/d Ijssel, The Netherlands)Netherlands Government
dc.description.sponsorshipPaediatric Oncology Centre Society for Research (KOCR, Rotterdam, the Netherlands)Netherlands Government
dc.description.sponsorshipGrupo Cooperativo Brasileiro para o Tratamento do tumour de Wilms (GCBTTW)
dc.description.sponsorshipSpanish Association Against Cancer (AECC)
dc.description.sponsorshipCancer Research UKCancer Research UK [C1010/A2889, C1188/A8687]
dc.description.sponsorshipNational Cancer Research Network
dc.description.sponsorshipSociete Francaise des Cancers de l'Enfant (SFCE)
dc.description.sponsorshipGesellschaft fur Paediatrische Onkologie und Haematologie (GPOH)
dc.description.sponsorshipChildren's Cancer and Leukemia Group (CCLG)
dc.description.sponsorshipSpanish Society of Paediatric Haematology and Oncology (SEHOP)
dc.description.sponsorshipSociedade Brasileira de Oncologia Pediatrica (SOBOPE)
dc.description.sponsorshipStichting Kinderoncologie Nederland (SKION)
dc.publisherELSEVIER SCI LTDeng
dc.relation.ispartofEuropean Journal of Cancer
dc.subject.otherdiffuse anaplasiaeng
dc.titleOutcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Groupeng
dc.rights.holderCopyright ELSEVIER SCI LTDeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng, Claudia:Gustave Roussy, Children & Adolescents Oncol Dept, Villejuif, France, Rhoikos:Saarland Univ Hosp, Dept Pediat Haematol Oncol, Homburg, Germany, Harm van:Netherlands Canc Inst, Biometr Dept, Amsterdam, Netherlands, Tomas:Hosp Maternoinfantil Carlos Haya, Dept Pediat, Malaga, Spain, Lisa:Alder Hey Childrens NHS Fdn Trust, Dept Oncol, Liverpool, Merseyside, England, Gordan:Sidra Med, Dept Pathol, Doha, Qatar, Jan:Marciniak Hosp Wroclaw, Dept Pediat Surg, Wroclaw, Poland; Med Univ, Dept Pediat Traumatol & Emergency Med, Wroclaw, Poland, Patrick:Saarland Univ Hosp, Dept Radiat Oncol, Homburg, Germany, Anne M.:Acad Med Ctr, Dept Radiol & Nucl Med, Amsterdam, Netherlands'HERMINE, Aurore:Hosp Enfants Armand Trousseau, Dept Pathol, Paris, France, Herve:Curie Inst, Dept Radiol, Paris, France, Kathy:UCL, Great Ormond St Inst Child Hlth, London, England, Christophe:Ctr Leon Berard, Pediat Oncohaematol Dept, Lyon, France, Beatriz de:Inst Nacl Canc, Pediat Oncohaematol, Rio De Janeiro, Brazil, Marry M. Van den:Princess Maxima Ctr Pediat Oncol, Oncol, Utrecht, Netherlands; Dutch Childhood Oncol Grp, The Hague, Netherlands, Norbert:Saarland Univ Hosp, Dept Pediat Haematol Oncol, Homburg, Germany, Arnauld C.:Hop La Timone, AP HM, Pediat Oncohaematol Dept, Marseille, France
hcfmusp.relation.referenceAbu-Ghosh AM, 2002, ANN ONCOL, V13, P460, DOI 10.1093/annonc/mdf028eng
hcfmusp.relation.referenceChagtai T, 2016, J CLIN ONCOL, V34, P3195, DOI 10.1200/JCO.2015.66.0001eng
hcfmusp.relation.referenceDaw NC, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.10032eng
hcfmusp.relation.referenceDome JS, 2006, J CLIN ONCOL, V24, P2352, DOI 10.1200/JCO.2005.04.7852eng
hcfmusp.relation.referenceFurtwangler R, 2011, KLIN PADIATR, V223, P113, DOI 10.1055/s-0031-1275293eng
hcfmusp.relation.referenceGraf N, 2012, EUR J CANCER, V48, P3240, DOI 10.1016/j.ejca.2012.06.007eng
hcfmusp.relation.referenceGREEN DM, 1994, J CLIN ONCOL, V12, P2126, DOI 10.1200/JCO.1994.12.10.2126eng
hcfmusp.relation.referenceHa TC, 2013, EUR J CANCER, V49, P194, DOI 10.1016/j.ejca.2012.07.010eng
hcfmusp.relation.referenceHol JA, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26849eng
hcfmusp.relation.referenceJimenez I, 2019, INT J CANCER, V144, P68, DOI 10.1002/ijc.31620eng
hcfmusp.relation.referenceKremens B, 2002, BONE MARROW TRANSPL, V30, P893, DOI 10.1038/sj.bmt.1703771eng
hcfmusp.relation.referenceLudwig N, 2015, PEDIATR BLOOD CANCER, V62, P1360, DOI 10.1002/pbc.25481eng
hcfmusp.relation.referenceOoms AHAG, 2016, CLIN CANCER RES, V22, P5582, DOI 10.1158/1078-0432.CCR-16-0985eng
hcfmusp.relation.referencePastore G, 2006, EUR J CANCER, V42, P2103, DOI 10.1016/j.ejca.2006.05.010eng
hcfmusp.relation.referenceReinhard H, 2004, KLIN PADIATR, V216, P132, DOI 10.1055/s-2004-822625eng
hcfmusp.relation.referenceSpreafico F, 2017, NAT REV UROL, V14, P3, DOI 10.1038/nrurol.2016.247eng
hcfmusp.relation.referenceTreger TD, 2018, TRANSL ONCOL, V11, P1301, DOI 10.1016/j.tranon.2018.08.006eng
hcfmusp.relation.referencevan den Heuvel-Eibrink MM, 2015, EUR J CANCER, V51, P498, DOI 10.1016/j.ejca.2014.12.011eng
hcfmusp.relation.referencevan den Heuvel-Eibrink MM, 2017, NAT REV UROL, V14, P743, DOI 10.1038/nrurol.2017.163eng
hcfmusp.relation.referenceVerschuur A, 2012, J CLIN ONCOL, V30, P3533, DOI 10.1200/JCO.2011.35.8747eng
hcfmusp.relation.referenceVujanic GM, 1999, MED PEDIATR ONCOL, V32, P317, DOI 10.1002/(SICI)1096-911X(199905)32:5<317::AID-MPO1>3.0.CO;2-Feng
hcfmusp.relation.referenceVujanic GM, 2002, MED PEDIATR ONCOL, V38, P79, DOI 10.1002/mpo.1276eng
hcfmusp.relation.referenceWegert J, 2017, J PATHOL CLIN RES, V3, P234, DOI 10.1002/cjp2.77eng
hcfmusp.relation.referenceWeirich A, 2004, ANN ONCOL, V15, P808, DOI 10.1093/annonc/mdh171eng
hcfmusp.relation.referenceZUPPAN CW, 1988, HUM PATHOL, V19, P1199, DOI 10.1016/S0046-8177(88)80152-7eng
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/ICr
Instituto da Criança - HC/ICr

Artigos e Materiais de Revistas Científicas - LIM/36
LIM/36 - Laboratório de Pediatria Clínica

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)1.45 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.